Barclays Initiates Coverage on Bruker (NASDAQ:BRKR)

Barclays assumed coverage on shares of Bruker (NASDAQ:BRKR) in a research report issued to clients and investors on Tuesday, Briefing.com reports. The brokerage set an “overweight” rating and a $75.00 price target on the medical research company’s stock. Barclays‘s target price suggests a potential upside of 18.30% from the company’s previous close.

BRKR has been the topic of a number of other research reports. TD Cowen reduced their price target on Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. Citigroup reduced their target price on Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Wells Fargo & Company initiated coverage on shares of Bruker in a research report on Tuesday, August 27th. They set an “overweight” rating and a $78.00 price objective for the company. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, The Goldman Sachs Group cut their price target on shares of Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $80.82.

Bruker Stock Down 1.8 %

BRKR stock opened at $63.40 on Tuesday. Bruker has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. The stock has a market capitalization of $9.21 billion, a price-to-earnings ratio of 23.05, a PEG ratio of 2.52 and a beta of 1.18. The business’s fifty day moving average price is $65.11 and its two-hundred day moving average price is $69.71.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, hitting analysts’ consensus estimates of $0.52. The business had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. Bruker’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period last year, the firm earned $0.50 earnings per share. On average, equities analysts anticipate that Bruker will post 2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Rise Advisors LLC bought a new stake in Bruker in the first quarter worth approximately $27,000. Covestor Ltd increased its stake in shares of Bruker by 139.1% in the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 210 shares in the last quarter. First Horizon Advisors Inc. increased its stake in shares of Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 218 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 354 shares during the period. Finally, Gordian Capital Singapore Pte Ltd bought a new position in Bruker during the second quarter worth $52,000. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.